Exemestane Offers New Option for Breast-Cancer Prevention

Exemestane is an aromatase inhibitor that substantially reduces the risk of invasive breast cancer in postmenopausal women at high risk of developing the disease. A 3yr follow up found that patients who took exemestane were 65% less likely to experience relapse than women who took tamoxifen or raloxifene, which reduce breast cancer risk by approximately 50% and 38%, respectively. I like this drug because it substantially reduces the incidence of relapse, has no serious toxic effects and results in only minimal changes in health-related quality of life.
Exemestane for Breast-Cancer Prevention.

NEW! GENE TARGETED NUTRACEUTICAL DIET FOR ESTROGEN POSITIVE BREAST CANCERS NOW AVAILABLE FOR DOWNLOAD


Speak Your Mind

*